TD Cowen Reiterates Buy Rating on Exact Sciences (EXAS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
Exact Sciences (EXAS) seeking 25% price hike on Cologuard Plus - TD Cowen
June 26, 2024 2:41 PM EDTTD Cowen analyst Dan Brennan reiterated a Buy rating and $80.00 price target on Exact Sciences (NASDAQ: EXAS) on news the company is seeing a 25% price hike for Cologuard (CG) Plus.
The analyst commented, "Yesterday, EXAS presented at the CLFS annual meeting seeking a... More
